LYELL IMMUNOPHARMA INC (LYEL) Stock Price, Quote, News and Overview
NASDAQ:LYEL - Nasdaq - US55083R1041 - Common Stock - Currency: USD
LYEL Quote, Performance and Key Statistics
0.7007
+0.04 (+6.17%)
The current stock price of LYEL is 0.7007 USD. In the past month the price increased by 19.94%. In the past year, price decreased by -70.68%.
LYEL Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About LYEL
Company Profile
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company is headquartered in South San Francisco, California and currently employs 224 full-time employees. The company went IPO on 2021-06-17. The firm's investigational therapies use the patient's own cells as the starting point to generate highly tumor-reactive, longer-lasting functional T cells with enhanced ability to resist exhaustion and kill cancer cells. Its technologies are designed to generate T cells with the ability to persist and self-renew while driving tumor cytotoxicity. Its two product candidates, LYL797 and LYL845, are in Phase I clinical development, and an additional product candidate, LYL119, is entering Phase I clinical development. The firm is also engaged in accelerating the development of IMPT-314, a dual-targeting CD19/20 chimeric antigen receptor (CAR) T-cell product candidate for hematologic malignancies, including B-cell non-Hodgkin lymphoma.
Company Info
LYELL IMMUNOPHARMA INC
201 Haskins Way, Suite 301
South San Francisco CALIFORNIA US
CEO: Elizabeth Homans
Employees: 224
Company Website: https://lyell.com/
Investor Relations: https://ir.lyell.com/
Phone: 16506950677
LYELL IMMUNOPHARMA INC / LYEL FAQ
What is the stock price of LYELL IMMUNOPHARMA INC today?
The current stock price of LYEL is 0.7007 USD. The price increased by 6.17% in the last trading session.
What is the ticker symbol for LYELL IMMUNOPHARMA INC stock?
The exchange symbol of LYELL IMMUNOPHARMA INC is LYEL and it is listed on the Nasdaq exchange.
On which exchange is LYEL stock listed?
LYEL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LYELL IMMUNOPHARMA INC stock?
9 analysts have analysed LYEL and the average price target is 0.82 USD. This implies a price increase of 16.45% is expected in the next year compared to the current price of 0.7007. Check the LYELL IMMUNOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LYELL IMMUNOPHARMA INC worth?
LYELL IMMUNOPHARMA INC (LYEL) has a market capitalization of 204.72M USD. This makes LYEL a Micro Cap stock.
How many employees does LYELL IMMUNOPHARMA INC have?
LYELL IMMUNOPHARMA INC (LYEL) currently has 224 employees.
What are the support and resistance levels for LYELL IMMUNOPHARMA INC (LYEL) stock?
LYELL IMMUNOPHARMA INC (LYEL) has a support level at 0.7 and a resistance level at 0.71. Check the full technical report for a detailed analysis of LYEL support and resistance levels.
Is LYELL IMMUNOPHARMA INC (LYEL) expected to grow?
The Revenue of LYELL IMMUNOPHARMA INC (LYEL) is expected to decline by -98.94% in the next year. Check the estimates tab for more information on the LYEL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy LYELL IMMUNOPHARMA INC (LYEL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LYEL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LYEL, evaluating the profitability, health, valuation and growth aspects
- LYELL IMMUNOPHARMA INC (LYEL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LYELL IMMUNOPHARMA INC (LYEL) Sales and EPS estimates to see what analysts future expectations are.
- LYELL IMMUNOPHARMA INC (LYEL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LYELL IMMUNOPHARMA INC (LYEL) Insider and Institutional Ownership to learn about the owners and their transactions.
- LYELL IMMUNOPHARMA INC (LYEL) Stock Chart to make your own analysis
- LYELL IMMUNOPHARMA INC (LYEL) Latest news and press-releases to stay up to date.
Does LYELL IMMUNOPHARMA INC (LYEL) stock pay dividends?
LYEL does not pay a dividend.
When does LYELL IMMUNOPHARMA INC (LYEL) report earnings?
LYELL IMMUNOPHARMA INC (LYEL) will report earnings on 2025-02-26, after the market close.
What is the Price/Earnings (PE) ratio of LYELL IMMUNOPHARMA INC (LYEL)?
LYELL IMMUNOPHARMA INC (LYEL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.79).
What is the Short Interest ratio of LYELL IMMUNOPHARMA INC (LYEL) stock?
The outstanding short interest for LYELL IMMUNOPHARMA INC (LYEL) is 4.96% of its float. Check the ownership tab for more information on the LYEL short interest.
LYEL Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to LYEL. When comparing the yearly performance of all stocks, LYEL is a bad performer in the overall market: 95.72% of all stocks are doing better.
LYEL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LYEL. While LYEL has a great health rating, there are worries on its profitability.
LYEL Financial Highlights
Over the last trailing twelve months LYEL reported a non-GAAP Earnings per Share(EPS) of -0.79. The EPS decreased by -27.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.94% | ||
| ROE | -38.44% | ||
| Debt/Equity | 0 |
LYEL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 47% to LYEL. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -2% and a revenue growth -98.94% for LYEL